Contract Notice Detail
Summary Information
Summary Information
Base Total Price:
11,779.269540 Euro
Request Reference:
10C0673124
Request Name:
Aquisição de Medicamentos do foro oncologico, ao abrigo do CPA 2023/491, para a ULSASI, para o ano 2024
Phase:
Tendering Phase
State:
Awarded
Description:
Aquisição de Medicamentos do foro oncologico, ao abrigo do CPA 2023/491, para a ULSASI, para o ano 2024
Procedure Type:
VortalGOV - Acquisition under a Framework Agreement (via Direct Award)
Lot Name
Lot Base Price
Expected Duration
B522 - BELIMUMAB [80 MG/ML; 120 MG/ 1,5 ML; PÓ P/A CONC P/A SOL P/A PERFUSÃO; FRS]
-
159
(
Days
)
B523 - BELIMUMAB [80 MG/ML; 400 MG/ 5 ML; PÓ P/A CONC P/A SOL P/A PERFUSÃO; FRS]
-
159
(
Days
)
C184 - CICLOFOSFAMIDA [1G; PÓ P/A SOL. INJ.; FRS]
-
159
(
Days
)
C187 - CICLOFOSFAMIDA [500MG; PÓ P/A SOL. INJ.; FRS]
-
159
(
Days
)
C228 - CISPLATINA (CONC P/ SOL P/ PERF) [1 MG/ ML; 50ML; FRS]
-
159
(
Days
)
E171 - ETOPOSIDO (CONC P/ SOL P/ PERF / SOL INJ) [20 MG/ML; 5ML; FRS]
-
159
(
Days
)
M133 - METOTREXATO (SOL INJ) [25MG/ ML; 2 ML; FRS]
-
159
(
Days
)
Object of the Contract
Object of the Contract
Type of Contract:
Supplies Acquisition
Main Object CPV Main Category:
Ic19 Amadora 2700 Venteira Amadora Lisboa PORTUGAL
CPV Main Vocabulary
33600000-6 - Pharmaceutical products
CPV Supplementary Vocabulary
Additional Classifications List
Scheduling
Scheduling
Request online publishing date:
7/25/2024 5:38 PM
(UTC +1 hour)
National official publishing date and time (DR):
9/4/2023 5:31 PM
(UTC +1 hour)
Due datetime for receiving replies:
7/30/2024 5:00 PM
(UTC +1 hour)
Financial Settings
Financial Settings
Define Warranties?
No
Contract Documents
Contract Documents
Document Name
Description
Doc Classification
Anexo II.xlsx
Anexo II.xlsx
Additional Information
Download
Convite 10C0673124.pdf
Convite 10C0673124.pdf
Instruction to tenderers
Download
Object of contract
This contract is subject to renewal?
No
The procurement is related to a project and/or programme financed by European Union funds?
No
Legal, economic, financial and technical information
The contract is reserved to sheltered workshops and economic operators aiming at the social and professional integration of disabled or disadvantaged persons?
No
Questionnaire
Questionnaire
1
Lot Title
B522 - BELIMUMAB [80 MG/ML; 120 MG/ 1,5 ML; PÓ P/A CONC P/A SOL P/A PERFUSÃO; FRS]
Base Price
389,760000
1.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
B522
BELIMUMAB [80 MG/ML; 120 MG/ 1,5 ML; PÓ P/A CONC P/A SOL P/A PERFUSÃO; FRS]
3,000000
UN
Buyer Comment:
500139962 | GlaxoSmithKline - Produtos Farmacêuticos, Lda. | CPA:2023491/68/0158 | NºAIM:5397971;
TOTAL
(The amounts shown do not include VAT)
2
Lot Title
B523 - BELIMUMAB [80 MG/ML; 400 MG/ 5 ML; PÓ P/A CONC P/A SOL P/A PERFUSÃO; FRS]
Base Price
4 322,200000
2.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
B523
BELIMUMAB [80 MG/ML; 400 MG/ 5 ML; PÓ P/A CONC P/A SOL P/A PERFUSÃO; FRS]
10,000000
UN
Buyer Comment:
500139962 | GlaxoSmithKline - Produtos Farmacêuticos, Lda. | CPA:2023491/68/0159 | NºAIM:5398003;
TOTAL
(The amounts shown do not include VAT)
3
Lot Title
C184 - CICLOFOSFAMIDA [1G; PÓ P/A SOL. INJ.; FRS]
Base Price
3 042,446040
3.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
C184
CICLOFOSFAMIDA [1G; PÓ P/A SOL. INJ.; FRS]
120,000000
UN
Buyer Comment:
503347345 | Baxter - Médico Farmacêutica, Lda. | CPA:2023491/110/0149 | NºAIM:4408480;
TOTAL
(The amounts shown do not include VAT)
4
Lot Title
C187 - CICLOFOSFAMIDA [500MG; PÓ P/A SOL. INJ.; FRS]
Base Price
288,540000
4.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
C187
CICLOFOSFAMIDA [500MG; PÓ P/A SOL. INJ.; FRS]
20,000000
UN
Buyer Comment:
503347345 | Baxter - Médico Farmacêutica, Lda. | CPA:2023491/110/0151 | NºAIM:4408381;
TOTAL
(The amounts shown do not include VAT)
5
Lot Title
C228 - CISPLATINA (CONC P/ SOL P/ PERF) [1 MG/ ML; 50ML; FRS]
Base Price
1 123,573500
5.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
C228
CISPLATINA (CONC P/ SOL P/ PERF) [1 MG/ ML; 50ML; FRS]
150,000000
UN
Buyer Comment:
502266791 | Hikma Farmacêutica, S.A. | CPA:2023491/62/0229 | NºAIM:5838412; 508622263 | Accord Healthcare, Unipessoal, Lda. | CPA:2023491/528/0549 | NºAIM:5316708;
TOTAL
(The amounts shown do not include VAT)
6
Lot Title
E171 - ETOPOSIDO (CONC P/ SOL P/ PERF / SOL INJ) [20 MG/ML; 5ML; FRS]
Base Price
2 588,250000
6.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
E171
ETOPOSIDO (CONC P/ SOL P/ PERF / SOL INJ) [20 MG/ML; 5ML; FRS]
170,000000
UN
Buyer Comment:
502266791 | Hikma Farmacêutica, S.A. | CPA:2023491/62/0240 | NºAIM:5829759; 506985261 | Sandoz Farmacêutica, Lda. | CPA:2023491/326/0638 | NºAIM:5171988; 508622263 | Accord Healthcare, Unipessoal, Lda. | CPA:2023491/528/0745 | NºAIM:5617964;
TOTAL
(The amounts shown do not include VAT)
7
Lot Title
M133 - METOTREXATO (SOL INJ) [25MG/ ML; 2 ML; FRS]
Base Price
24,500000
7.1
Bill of Quantities
*
This price list has extra requirements. Make sure everything is completed, under each article line.
Item Code
Description
Quantity
Unit
M133
METOTREXATO (SOL INJ) [25MG/ ML; 2 ML; FRS]
5,000000
UN
Buyer Comment:
507045491 | Teva Pharma - Produtos Farmacêuticos, Lda. | CPA:2023491/334/0100 | NºAIM:2494888; 508622263 | Accord Healthcare, Unipessoal, Lda. | CPA:2023491/528/0583 | NºAIM:5481270;
TOTAL
(The amounts shown do not include VAT)
Evaluation
Evaluation
Vision
Avaliação
Definir modelo de avaliação
Sim
Não
Modalidade de avaliação
Selecione…
Monofator
Método de Avaliação
Selecione…
Manual
Divulgar critérios de avaliação
Sim
Não
Critérios da Avaliação
1 - B522 - BELIMUMAB [80 MG/ML; 120 MG/ 1,5 ML; PÓ P/A CONC P/A SOL P/A PERFUSÃO; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
-
100%
Normas de desempate
2 - B523 - BELIMUMAB [80 MG/ML; 400 MG/ 5 ML; PÓ P/A CONC P/A SOL P/A PERFUSÃO; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
-
100%
Normas de desempate
3 - C184 - CICLOFOSFAMIDA [1G; PÓ P/A SOL. INJ.; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
-
100%
Normas de desempate
4 - C187 - CICLOFOSFAMIDA [500MG; PÓ P/A SOL. INJ.; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
-
100%
Normas de desempate
5 - C228 - CISPLATINA (CONC P/ SOL P/ PERF) [1 MG/ ML; 50ML; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
-
100%
Normas de desempate
6 - E171 - ETOPOSIDO (CONC P/ SOL P/ PERF / SOL INJ) [20 MG/ML; 5ML; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
-
100%
Normas de desempate
7 - M133 - METOTREXATO (SOL INJ) [25MG/ ML; 2 ML; FRS]
Critérios da Avaliação
Descrição
Tipo de Fator
Peso (%)
1.
Preço
-
100%
Normas de desempate
Public Messages
Public Messages
Type
Reference
Subject
Date
No items found...